Market Slip Drags Injective Down 16% Despite Ongoing Developments
Summary
On August 30th, Injective (INJ) experienced a 16% decline, diminishing short-term recovery prospects amid a bearish market. Despite this, on-chain developments continue, reinforcing Injective's community presence. The release of the web-based Remix IDE allows developers to create on-chain applications without installation hassles, featuring code templates for ease of use. Injective's collaboration with Helios aims to address cross-chain identity verification through a 10-day "Collabathon" starting September 2nd. Currently, INJ trades below $18.02, with potential for a rally if market conditions improve. Long-term targets for INJ are set at $23.37, though caution is advised due to overall market volatility.
